GlassScriptPhysician profile
Jory G Croft
NPI 1245570613
$674.52
in general payments reported to CMS, 2019-2025
13 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.05 · 2022: $18.84 · 2023: $133 · 2024: $195 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $607.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $198.79 | 2024-2025 | Cabenuva, Dovato, Apretude |
| Glaxosmithkline, LLC. | $120.30 | 2023-2025 | Bexsero, Shingrix, Arexvy |
| Theratechnologies INC. | $100.86 | 2024-2025 | Trogarzo, Egrifta |
| Merck Sharp & Dohme LLC | $51.09 | 2022-2025 | Proquad, Gardasil 9, M-M-R II |
| Takeda Pharmaceuticals U.S.A., INC. | $34.11 | 2021 | |
| Abbvie INC. | $29.52 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $27.22 | 2024-2025 | Farxiga, Airsupra |
| Heron Therapeutics, INC. | $23.85 | 2023 | Zynrelef |
| Indivior INC. | $23.51 | 2025 | Sublocade |
| Novo Nordisk INC | $21.55 | 2025 | Ozempic |
| Pfizer INC. | $15.31 | 2024 | |
| Lilly USA, LLC | $14.47 | 2024 | Mounjaro |
| Adlon Therapeutics L.P. | $13.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jory Croft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.